The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 49.70
Bid: 49.80
Ask: 49.95
Change: -0.80 (-1.58%)
Spread: 0.15 (0.301%)
Open: 50.00
High: 50.60
Low: 49.30
Prev. Close: 50.50
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DBSP awards; Director/PDMR shareholding

25 Apr 2022 18:09

RNS Number : 2734J
IP Group PLC
25 April 2022
 

FOR RELEASE ON

25 APRIL 2022

 

IP Group plc - DBSP awards; Director/PDMR shareholding

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, announces the following in connection with its employee share schemes.

 

Deferred Bonus Share Plan ("DBSP") Awards

 

IP Group has granted nil-cost options over ordinary shares of two pence each ("Shares") to the executive directors and persons discharging managerial responsibilities ("PDMRs") under the Group's DBSP on 21 April 2022. The grants reflect the deferral of fifty per cent of each person's award above £25,000 under the Group's Annual Incentive Scheme ("AIS") in respect of the Group's performance for the financial year ended 31 December 2021. The following table sets out details of the awards made to the Executive Directors and PDMRs: 

 

Name of Director/PDMR

Structure of award

Number of options granted

Total number of options currently held

Greg Smith

Nil-Cost Option

176,200

298,403

David Baynes

Nil-Cost Option

150,902

269,013

Sam Williams

Nil-Cost Option

82,364

153,086

Mark Reilly

Nil-Cost Option

94,736

160,210

Angela Leach

Nil-Cost Option

58,224

102,758

Christopher Glasson

Nil-Cost Option

41,088

64,980

Lisa Patel

Nil-Cost Option

3,680

5,970

Liz Vaughan-Adams

Nil-Cost Option

38,272

52,664

Moray Wright

Nil-Cost Option

84,876

88,260

Dan Xie

Nil-Cost Option

29,790

44,874

Anthony York

Nil-Cost Option

33,498

33,498

Total

 

793,630

1,273,716

 

In addition to the above, awards over a total of 1,272,544 Shares were made to certain other of the Group's employees. As at the date of this announcement, a total of 3,377,871 nil-cost options over Shares remain outstanding under the IP Group DBSP.

 

No consideration was paid for the grant of the awards and no consideration is due on the maturity of the option period. Fifty per cent of the options will normally be automatically exercised on 31 March 2023 and fifty per cent on 31 March 2024, with each such automatic exercise generally subject to continued employment.

Shares in issue

At the date of this announcement, the Company continues to have 1,063,033,287 Shares in issue and 28,938,473 Shares held in treasury.

 

The following information is being disclosed pursuant to the requirements of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

DBSP awards

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Greg SmithDavid BaynesSam WilliamsMark ReillyAngela LeachChristopher Glasson

Lisa Patel

Liz Vaughan-Adams

Moray Wright

Dan Xie

Anthony York

2

Reason for the notification

a)

Position/status

Director Chief Executive OfficerDirector Chief Operating and Financial OfficerPDMR Managing Partner, Life SciencesPDMR Managing Partner, TechnologyPDMR General Counsel & Company Secretary

PDMR Finance Director

PDMR Partner, Employee Executive

PDMR Director of Communications

PDMR CEO Parkwalk

PDMR Partner, Employee Executive

PDMR Group People Director

 

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IP Group plc

b)

Legal Entity Identifier

213800HG22UM138WFG43

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 2p each in IP Group plc

 

 ISIN: GB00B128J450

b)

Nature of the transaction

Grant of nil-cost options under the IP Group plc DBSP

c)

Currency

GBP

d)

Price(s) and volume(s)

Name(s)

Price(s)

Volume(s)

Greg Smith

Nil cost option

176,200

David Baynes

Nil cost option

150,902

Sam Williams

Nil cost option

82,364

Mark Reilly

Nil cost option

94,736

Angela Leach

Nil cost option

58,224

Christopher Glasson

Nil cost option

41,088

Lisa Patel

Nil cost option

3,680

Liz Vaughan-Adams

Nil cost option

38,272

Moray Wright

Nil cost option

84,876

Dan Xie

Nil cost option

29,790

Anthony York

Nil cost option

33,498

 

e)

Aggregated information

-Aggregated volume

- Price

- Aggregated total

 

Aggregated number of options granted under the DBSP to Directors and PDMRs on 21 April 2022: 793,630

Price: £ nil

f)

Date of the transaction

21 April 2022

g)

Place of the transaction

Outside a trading venue

 

 

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

 

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech. The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK's leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUVRBRUWUSUAR
Date   Source Headline
11th Dec 20187:00 amRNSWaveOptics completes £20.0m funding round
10th Dec 20187:05 amRNSAvacta signs deal with LG Chem worth up to $310m
4th Dec 20185:49 pmRNSPortfolio co Ceres finalises deal with Weichai
3rd Dec 20187:00 amRNSUltrahaptics completes £35.0m funding round
31st Oct 20185:52 pmRNSDirector Declaration
18th Oct 20182:00 pmRNSAmgen invests £50m in Oxford Nanopore Technologies
15th Oct 20187:00 amRNSPortfolio co Garrison completes £22.9m financing
8th Oct 20187:07 amRNSPortfolio co Diurnal headline data for Chronocort
19th Sep 20189:51 amRNSDirector/PDMR Shareholding
17th Sep 20184:58 pmRNSDirector/PDMR Shareholding
17th Sep 20184:38 pmRNSDirector/PDMR Shareholding
17th Sep 201812:12 pmRNSDirector/PDMR Shareholding
17th Sep 20187:00 amRNSAppointment of Chairman; Board changes
31st Aug 20189:55 amRNSHolding(s) in Company
30th Aug 20187:00 amRNSGenomics announces Vertex leads £25m financing
29th Aug 20186:29 pmRNSIP Group plc -SAYE scheme
21st Aug 20187:06 amRNSCeres signs agreement with Bosch; £9m investment
10th Aug 20187:11 amRNSArtios Pharma completes £65m financing
31st Jul 20188:40 amRNSTR-1: NOTIFICATION
25th Jul 20187:00 amRNSHalf-yearly results
6th Jul 20187:00 amRNSNotification of Major Interest in Shares
4th Jul 20182:40 pmRNSCeres Power announces £20m fundraising
2nd Jul 20187:00 amRNSHolding(s) in Company
27th Jun 20187:30 amRNSCarisma announces $53m Series A funding round
27th Jun 20187:00 amRNSNotification of Major Interest in Shares
22nd Jun 201810:00 amRNSAppointment of Joint Broker
18th Jun 20181:37 pmRNSResult of AGM
7th Jun 20186:00 pmRNSHolding(s) in Company
6th Jun 20189:26 amRNSMicrobiotica signs collaboration worth up to $534m
16th May 201810:49 amRNSPortfolio co Ceres partners with Weichai Power
16th May 20187:00 amRNSNotice of AGM; Annual Report
11th May 20187:00 amRNSDirector/PDMR Shareholding
10th May 20186:18 pmRNSDirector/PDMR Shareholding
9th May 20185:31 pmRNSDirector share purchase
4th May 20187:00 amRNSBoard changes
30th Apr 20187:00 amRNSTotal Voting Rights
16th Apr 20185:45 pmRNSDirector/PDMR Shareholding
12th Apr 20189:19 amRNSEnterprise Therapeutics raises £29m
5th Apr 20181:12 pmRNSIP Group plc - Issue of Equity
4th Apr 201811:46 amRNSIP Group plc - Director/PDMR share purchase
29th Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSOxford Nanopore announces £100m fundraising
17th Jan 201811:53 amRNSHolding(s) in Company
10th Jan 20189:12 amRNSHolding(s) in Company
2nd Jan 20187:00 amRNSTotal Voting Rights
18th Dec 201710:15 amRNSAutifony signs Eur627.5m agreement with BI
15th Dec 201712:50 pmRNSDiurnal receives positive CHMP opinion for Alkindi
14th Dec 20174:48 pmRNSDirectorate Change
13th Dec 20172:27 pmRNSIssue of Equity
8th Dec 20177:05 amRNSMirriad raises £26.2m; proposed admission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.